Description
Triptorelin is a synthetic decapeptide of ten amino acids and belongs to the class of GnRH agonists (gonadotropin-releasing hormone agonists, also called LHRH agonists). It is derived from endogenous GnRH but differs by a single substitution at position 6: glycine is replaced by D-tryptophan. According to research this modification makes the molecule far more resistant to enzymatic breakdown and increases receptor affinity to roughly one hundred times that of native GnRH.
The mechanism is biphasic and sits at the center of research with this compound. In the first phase Triptorelin acts as an agonist and stimulates the pituitary to release more gonadotropins (LH and FSH) - the so-called flare-up. In animal models an initial testosterone rise was observed after administration, followed by rapid suppression within a few days. Under continuous receptor occupancy the GnRH receptors undergo downregulation and desensitization, which subsequently suppresses gonadotropin release. This switch from stimulation to suppression is the core of research interest in GnRH agonists.
On pharmacokinetics: the native elimination half-life is reported at around five hours. With subcutaneous administration, the biological residence time extends to roughly ten times that of intravenous dosing due to slow release from the depot at the injection site. Peak plasma concentrations are described in the literature after one to three hours. Most studies work with depot formulations whose kinetics differ from immediate-release dosing.
Triptorelin is a research compound from the field of hormone and endocrinology research. At TPD you receive it as a 10-pack with 2mg per vial. The substance is intended exclusively for research and educational purposes.
This information is for research and educational purposes only. Not medical advice.
Studies
- An analytical strategy to characterize the pharmacokinetics and pharmacodynamics of triptorelin in rats - Anal Bioanal Chem 2014 (preclinical, rat model): shows the characteristic PK/PD profile with an initial testosterone flare-up, rapid suppression within 5 days, and sustained suppression until the next dose.
- Triptorelin for the treatment of endometriosis - Expert Opin Pharmacother 2014: review of the mechanism of action, pharmacokinetics, and pharmacodynamics of the decapeptide.
- Effects of a long-acting GnRH analog (Triptorelin) on the pituitary-ovarian-adrenal axis - Metabolism 1996: documents the suppression of FSH, LH, and estradiol as well as the initial flare-up phenomenon in adrenal steroids after a single dose.
- Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer - Reprod Biol Endocrinol 2003 (in vitro): mechanism study on GnRH receptor signal transduction and antiproliferative effects in cell lines.
- GnRH agonist vs. hCG for triggering of ovulation - differential effects on gene expression - PLoS One 2014: compares the effects of GnRH agonist triggers on gene expression in human granulosa cells.
Stack Notes
- Combined with HCG for research designs on testicular axis behavior: HCG mimics the LH signal directly at the testis, while Triptorelin acts via the pituitary. Different entry points into the same axis.
- Gonadorelin Acetate is the native GnRH counterpart without the D-Trp6 substitution. Comparing pulsatile native GnRH against the long-acting agonist is a classic research setup for GnRH receptor dynamics.
- Enclomiphene (Androxal) acts at the estrogen receptor in the pituitary and addresses the HPG axis from another angle - relevant for comparative research on central vs. peripheral modulation of gonadotropin release.
- With Clomid (Clomifen) or Tamoxifen (Nolvadex) as SERM references for research on gonadotropin regulation. Both modulate estrogen feedback at the pituitary, a different lever than the GnRH receptor.
- Arimidex (Anastrozole) intervenes in estrogen metabolism as an aromatase inhibitor. In hormone axis research models it is often studied as a complementary entry point alongside the GnRH level.
